Latest publications

Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results. Van der Gang LF, Atash K, Zuithoff NPA, Haeck I, Boesjes CM, Bacoş-Cosma OI et al. J Eur Acad Dermatol Venereol 2025 Apr 03

Severity of almond allergy and diagnostic value of almond extract in adults. Kallen EJJ, Welsing PMJ, Alves PB, Kuiken JE, Knulst AC, Van Ree R et al. J Allergy Clin Immunol Pract 2025 Mar 27

Dupilumab-Associated Ocular Surface Disease in Paediatric Atopic Dermatitis Patients: Results From the BioDay Registry. Van der Rijst LP, Van Luijk CM, Van der Kamp S, Zuithoff NPA, De Boer JH, De Bruin-Weller MS et al. Clin Exp Allergy 2025 Mar 18

Ocular surface disease in pediatric patients with moderate-to-severe atopic dermatitis. Van der Rijst LP, Veldhuis N, Van der Kamp S, Achten RE, Van Luijk CM, Voskuil-Kerkhof ESM et al. Pediatr Allergy Immunol 2025 Feb; 36(2):e70040

Increased Levels of Inflammatory Proteins, Including TARC/CCL17, in Skin of AD Patients During JAK Inhibitor Treatment. Boesjes CM, Van der Gang LF, Bakker DS, Den Hartog Jager CF, De Graaf M, De Bruin-Weller MS et al. Clin Exp Allergy 2025 Mar; 55(3):260-263

Increasing dosing intervals for biologics in atopic dermatitis-why, who, when and how? Jacobson ME, Boesjes CM, De Bruin-Weller MS, De Graaf M, Morimoto RY, Simpson EL et al. J Eur Acad Dermatol Venereol 2025 Jan 22

Exploring Social Health in Patients with Atopic Dermatitis: An Observational, Cross-sectional, Questionnaire Based Study on Social Participation and Emotional Support. Kamphuis E, Loman L, De Bruin-Weller M, Schuttelaar ML et al. Acta Derm Venereol 2025 Jan 08; 105:adv41129

The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trials. Guttman-Yassky E, Rosmarin D, De Bruin-Weller M, Weidinger S, Bieber T, Hong HC et al. J Am Acad Dermatol 2025 May; 92(5):1024-1031

Improvement in quality of life in patients treated with lebrikizumab monotherapy is mediated by improvement in itch and sleep: Results from two Phase 3 trials in patients with moderate-to-severe atopic dermatitis. Yosipovitch G, De Bruin-Weller M, Wiseman M, Elberling J, Gutermuth J, Pierce E et al. Clin Exp Dermatol 2024 Dec 16

Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28-Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels. Dekkers C, Zuithoff N, Bakker D, Knol E, Wevers A, Touwslager W et al. Allergy 2025 Apr; 80(4):1060-1073

Type 2 Immune-Dominant Endotype Is Not Associated With Increased Responsiveness to Dupilumab Treatment in Adult Atopic Dermatitis Patients. Dekkers C, Smits H, Stölzl D, Spekhorst L, Knol E, Van Wijk F et al. Clin Exp Allergy 2025 Jan; 55(1):97-99

Assessing Disease Control in Patients with Atopic Dermatitis by Using the Atopic Dermatitis Control Tool in Daily Practice. Chen R, Loman L, Van der Gang LF, Sloot MM, De Bruin-Weller MS, Schuttelaar MLA et al. Dermatology 2024; 240(5-6):732-738

Drug Survival of Dupilumab, Methotrexate, and Cyclosporine A in Children With Atopic Dermatitis. Van der Rijst LP, Kamphuis E, Schuttelaar MLA, Hurmuz R, Seyger MMB, Caron AGM et al. JAMA Dermatol 2025 Jan 01; 161(1):12-21

Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year results from PEDIatric STudy in Atopic Dermatitis. Paller AS, De Bruin-Weller M, Marcoux D, Baselga E, Oliveira de Carvalho V, Ardusso LRF et al. J Am Acad Dermatol 2025 Feb; 92(2):242-251

Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study. Soegiharto R, Alizadeh Aghdam M, Sørensen JA, Van Lindonk E, Bulut Demir F, Mohammad Porras N et al. Allergy 2025 Feb; 80(2):489-499